---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-055806"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:50:26.139220+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AbCellera Q3 net loss $21.4M ($0.08/share); revenue falls to $5.5M from $9.4M

## Summary
- Total revenue $5.5M, down 41% from $9.4M in Q3 2020 due to lower milestone payments and bamlanivimab royalty pause.
- Net loss $21.4M ($0.08 loss per share) vs net loss $2.7M ($0.02 loss) in Q3 2020.
- Cumulative program starts 69, up 35% YoY; partners increased to 35; 5 molecules in the clinic.
- Acquired TetraGenetics to expand capabilities for high-value transmembrane protein targets.
- Post-quarter: Eli Lilly ordered 614K additional doses of bamlanivimab with etesevimab; shipments resumed.

## SEC filing metadata
- accession: 0001564590-21-055806
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000156459021055806/0001564590-21-055806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000156459021055806/abcl-8k_20211109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-055806
- JSON: https://secwatch.observer/filing/0001564590-21-055806.json
- Plain text: https://secwatch.observer/filing/0001564590-21-055806.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.